Humans ; Medicine, Chinese Traditional ; Psoriasis ; classification ; diagnosis ; therapy ; Syndrome

Objective To determine the value of soluble triggering receptor expressed on myeloid cells 1 (sTREM-1) in patients with stable chronic obstructive pulmonary disease (sCOPD). Methods From 2015 January to 2015 August, 101 patients with stable chronic obstructive pulmonary disease and 81 healthy controls were en-rolled. All subjects underwent pulmonary function test to record FEV1%pred and FEV1%FVC and their serum sTREM-1 levels were determined. Arterial blood gas analyses and COPD assessment tests were also conducted in stable COPD patients. Results Serum sTREM-1 levels were significantly higher in stable COPD patients than healthy controls (113.2 ± 31.5 pg/mL and 83.8 ± 17.9 pg/mL respectively, P=0.000). sTREM-1 levels were posi-tively correlated with CAT score (r=0.507, P=0.000), whereas negatively correlated with FEV1%pred and PaO2 (r = 0.507, P = 0.000; r = 0.439, P = 0.000). Conclusion sTREM-1 is a promising biomarker to evaluate sCOPD in the future.

To improve the quality of full English teaching of urology for foreign students,our experiences are: choose the excellent teaching staff,choose and prepare teaching material carefully,make CAI courseware accurately and popularly,enrich teaching component,pay attention to the background of the foreign students,and apply new teaching model with communications.

Objective To activate the microglia cells by using thrombin,and then to observe the effect of precondition of rosiglitazone (RGZ)-pretreated on the expression change of peroxisome proliferator-activated receptor-γ (PPARγ),nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase (NQO1) and γ-glutamylcysteine synthetase (γ-GCS).Methods Microglia cells were obtained from the brain tissues of the newborn rats and were primary cultured in vitro.The microglia cells were isolated in 14 days.The isolated microglia cells were randomly devided into normal control group (control group),thrombin stimulation group (stimulation group) and rosiglitazone intervention group (RGZ + TH group).The PPARγ,NQO1 and γ-GCS were observed by immunocytochemistry and real-time polymerase chain reaction (RT-PCR) methods.Results The immunocytochemistry showed that the number of stained cells of PPARγ,NQO1 and γ-GCS in stimulation group and RGZ + TH group were increased remarkably as compared with the control group.A significant increase of the PPARγ,NQO1 and γ-GCS was observed in the RGZ + TH group compared to the others.The RT-PCR method demonstrated that the expressions of PPARγ mRNA(211.88 ± 58.75),NQO1 mRNA(182.67 ± 62.09) and γ-GCS mRNA (188.17 ± 57.06) in RGZ + TH group were increased significantly as compared with the stimulation group (119.19 ± 44.58,101.73±32.19,108.81 ±19.71) or the control group (0.34±0.21,0.73±0.46,0.30±0.13;F=181.50,286.63,614.43,all P ＜ 0.01).Conclusion Medium-dose rosiglitazone-pretreated might increase the expression of PPARγ,NQO1 and γ-GCS in microglia cells activated by thrombin.Rosiglitazone might activate the PPARγso that increase its downstream gene to achieve its anti-oxidative stress effects.

Acupuncture Points ; Acupuncture Therapy ; Chronic Disease ; therapy ; Edema ; therapy ; Heart Failure ; therapy ; Humans ; Male ; Middle Aged

AIM:To observe the effect of rosiglitazone (RGZ) pretreatment on the expression of peroxisome proliferator-activated receptor γ( PPARγ) , nuclear factor E2-related factor 2 ( Nrf2 ) and heme oxygenase-1 ( HO-1 ) in the microglia cells activated by thrombin.METHODS:Microglia cells were obtained from the brain tissues of the newborn rats and were primarily cultured in vitro.After cultured for 14 d, the microglia cells were used in the experiment.The iso-lated microglia cells were randomly divided into normal control group, thrombin stimulation group ( TH group) , rosiglita-zone intervention group ( RGZ +TH group ) and retinoic acid intervention group ( RA +TH group ) .The expression of PPARγ, Nrf2 and HO-1 was observed by immunocytochemistry, real-time PCR and Western blot.RESULTS:The number of positive staining cells of PPARγ, Nrf2 and HO-1 in TH group, RGZ+TH group and RA+TH group were increased re-markably as compared with control group.The significant increases in PPARγ, Nrf2 and HO-1 were observed in RGZ+TH group compared with other groups.The mRNA expression of PPARγ, Nrf2 and HO-1 in RGZ+TH group was increased significantly as compared with TH group, control group or RA+TH group (P<0.01), Besides, the mRNA expression of Nrf2 and HO-1 in RA+TH group was decreased as compared with TH group or RGZ+TH group (P<0.01).The protein levels of PPARγ, Nrf2 and HO-1 in RGZ+TH group were significantly increased as compared with TH group, control group or RA+TH group (P<0.01).The protein expression of Nrf2 and HO-1 in RA+TH group was decreased as com-pared with TH group or RGZ+TH group (P<0.01).CONCLUSION:Rosiglitazone pretreatment might increase the ex-pression of PPARγ, Nrf2 and HO-1 in the microglia cells activated by thrombin.By inhibiting the expression of Nrf2 after RA pretreatment, the expression of the downstream gene HO-1 is also influenced.The anti-oxidative stress effects of rosigli-tazone might be achieved partly by modulating Nrf2 to control the downstream gene HO-1.

OBJECTIVE:To observe the clinical efficacy of prostaglandin E1 used early in patients after renal transplantation. METHODS:93 renal transplant recipients (treatment group) were treated with PGE1(20 ?g?d-1) within 2 weeks after operation,and another 85 renal transplant recipients (control group) were not given PGE1 therapy in the same period. Urine volume,serum creatinine (Scr),blood flow resistance-indexes (RI) under Doppler color ultrasound,incidences of acute rejection (AR) and delayed graft function (DGF) and the 1 year patient/graft survival rates were compared between the two groups. RESULTS:The 24h urine volume in the treatment group on day 1 after operation was significantly higher than in the control group (9.40?1.9 L vs. 8.11?1.8L) (P

OBJECTIVE:To evaluate the efficacy and safety of early use of rapamycin in renal transplant recipients.METHODS:A total of 58 patients undergoing renal transplantation(with kidneys came from corpses)were assigned to receive cyclosporine A(CsA)plus rapamycin(RPM)and prednisone(trial group,n=28)or CsA plus mycophenolate(MMF)and prednisone(control group,n=30).The clinical efficacy at 6 months after renal transplantation,the complications and the adverse drug reactions of the two groups were observed,meanwhile,biochemical indicators including serum blood lipid level and hepatic and renal functions were monitored to analyze the effects of two immunosuppressive schemes on acute rejection of the transplanted kidneys and the survival rates of patients/kidneys.RESULTS:The transplanted kidneys in both group all survived with function.There was no significant difference between the two groups in the incidence of acute rejection(4/28(14.3%)for trial group vs.5/30(16.7%)for control group).The abnormal serum lipid level,infection of incisional wound,diarrhea and hypoleukemia were noted in 11 cases(39.3%),4 cases(14.3%),3 cases(10.7%)and 1 case(3.6%)for the trial group vs.3 cases(10.0%),2 cases(6.7%),8 cases(26.7%)and 5 cases(16.7%)for the control group.CONCLUSION:The early use of triple immunosuppressive therapy(CsA + RPM+ Pred)showed more potent immunosuppressive efficacy but fewer acute rejections as compared the control group(CsA + MMF + Pred).The main side effects of the trial group(CsA +RPM+ Pred)manifested as increased serum lipid level and infection of incisional wound,however,the incidences of diarrhea and hypoleukemia were significantly lower than in the control group.

Objective To compare the pharmacokinetic profile of propofol after a single intravenous dose during induction in the elderly and young patients. Methods Eighteen ASA I-II patients undergoing elective gastro-intestinal and intracranial surgery were studied. Patients with abnormal liver and/or kidney function were excluded. The patients were premedicated with intramuscular phenobarbital 100mg and scopolamine 0.3mg 1h before operation. The patients were divided into two groups according to their age; the young and middle-aged group, aged between 31-57, on average 46. 5yr (A, n=6); the elderly group, aged between 67-81 yr, on average 74.6 yr(E, n = 12) . Group E was further divided into two subgroups: E1 aged between 67-73 yr, on average 69 .3 yr (n = 6); E2 aged between 76-81 yr,on average 78. 7 yr ( n=6 ) . In group A anesthesia was induced with propofol 1 . 5rng kg-1 , midazolam 0.03-0.06mg kg-1 , fentanyl 3-5ugkg-1 and vecuronium 0. 1 mgkg-1 . In group E propofol 1.0 mgkg-1 was given but the doses of the other three drugs for induction were the same as in group A. Anesthesia was maintained with isoflurane 0.5%-2.0% supplemented with intermittent iv boluses of fentanyl, vecuronium and midazolam. ECG, BP, SpO2 , PET CO2 , CVP and urine output were continuously monitored during anesthesia. Propofol was given in bolus through the vein in the forearm slowly over 30-45 s, and blood samples were taken from internal jugular vein before propofol injection and 1 ,2,4 ,6,10,15,30,45,60,75, 90,120 ,150 ,180,240 ,300,360min after the end of propofol injection for measurement of plasma propofolconcentration by HPLC with fluorescence detection. Results The pharmacokinetics of propofol in the 18 patients were best described by a three compartment pharmacokinetic model. The dose-corrected mean plasma concentrations of propofol in group A were lower at 1,2,4,6,10 min after the end of propofol injection (P